Cardiogenic shock after ocrelizumab infusion in relapsing-remitting multiple sclerosis
Published online on December 31, 2025
Abstract
Multiple Sclerosis Journal, Ahead of Print.
A 42-year-old man with relapsing-remitting multiple sclerosis and no prior cardiac history developed a severe but reversible left ventricular systolic dysfunction following ocrelizumab administration. Symptoms started 24–36 hours after the infusion and ...
A 42-year-old man with relapsing-remitting multiple sclerosis and no prior cardiac history developed a severe but reversible left ventricular systolic dysfunction following ocrelizumab administration. Symptoms started 24–36 hours after the infusion and ...